生物制药公司Arvinas（股票代码：ARVN）周五盘中股价大涨5.12%，引发市场关注。这一涨势出现在多家华尔街分析师大幅下调该公司目标股价之际，形成鲜明对比。
根据最新消息，包括BTIG、杰富瑞、Piper Sandler、巴克莱和古根海姆在内的多家机构，纷纷将Arvinas的目标价从原先的24-69美元区间大幅下调至10-16美元区间。其中，杰富瑞更是将评级从"买入"下调至"持有"。这些分析师行动通常会对股价产生负面影响，但Arvinas股价却出现逆势上涨。
分析人士认为，在如此多的下调评级后，Arvinas股价不跌反涨，可能反映出市场对该公司基本面的某些积极看法。投资者可能认为股价已经充分反映了负面因素，现在处于被低估的状态。然而，考虑到分析师的普遍悲观态度，投资者仍需谨慎关注该公司未来的业务发展和财务表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.